Invivo CART will have to move up to earlier lines of treatments before chronically exhausted T cells build up in patients. That is a basic problem for tigit and bi-specific .... too. Even invivo myeloid cells will not fix that fundamental problem facing dying cancer patients.
Market Data 
Markets 
AI
